Editor’s Highlight: Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach

Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for idiosyncratic drug-induced liver injury (DILI) in this patient population. To identify risk factors and mechanisms underlying t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Toxicol Sci
Main Authors: Mosedale, Merrie, Kim, Yunjung, Brock, William J., Roth, Sharin E., Wiltshire, Tim, Eaddy, J. Scott, Keele, Gregory R., Corty, Robert W., Xie, Yuying, Valdar, William, Watkins, Paul B.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Collaborative Cross and Tolvaptan-Induced Liver Injury
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6075566/
https://ncbi.nlm.nih.gov/pubmed/28115652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/toxsci/kfw269
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados